CN106138055A - A kind of Ketoconazol/Clobetasol Propionate liniment and preparation method thereof - Google Patents
A kind of Ketoconazol/Clobetasol Propionate liniment and preparation method thereof Download PDFInfo
- Publication number
- CN106138055A CN106138055A CN201610611441.4A CN201610611441A CN106138055A CN 106138055 A CN106138055 A CN 106138055A CN 201610611441 A CN201610611441 A CN 201610611441A CN 106138055 A CN106138055 A CN 106138055A
- Authority
- CN
- China
- Prior art keywords
- liniment
- ketoconazol
- clobetasol propionate
- stirring
- polyvinyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 title claims abstract description 26
- 229960004125 ketoconazole Drugs 0.000 title claims abstract description 26
- 239000000865 liniment Substances 0.000 title claims abstract description 20
- 229940040145 liniment Drugs 0.000 title claims abstract description 20
- 229960004703 clobetasol propionate Drugs 0.000 title claims abstract description 15
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 13
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 11
- 239000011975 tartaric acid Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 150000003851 azoles Chemical class 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 241000233866 Fungi Species 0.000 abstract description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000037384 skin absorption Effects 0.000 abstract description 2
- 231100000274 skin absorption Toxicity 0.000 abstract description 2
- 230000000699 topical effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Ketoconazol/Clobetasol Propionate liniment, represent with weight portion, represent with weight portion, including ketoconazole 0.1 ~ 1.6g, tartaric acid 10 ~ 25g, Oleum menthae 5 ~ 15ml, polyvinyl alcohol 20 ~ 80g, ethylene glycol 50 ~ 150g, methyl hydroxybenzoate 1.2 ~ 3.6g, ethanol solution 200 ~ 600ml, enough purified water.After this liniment is applied to skin film forming, fungus, yeast, dimorphic fungus and the Mycophytes of skin surface being had antibacterial and bactericidal action, local topical, hardly through skin absorption, is used conveniently and safely, and therapeutic effect is good.
Description
Technical field
The present invention relates to liniment preparing technical field, specifically refer to a kind of Ketoconazol/Clobetasol Propionate liniment and preparation side thereof
Method.
Background technology
Ketoconazole is off-white color crystalline powder；Odorless, tasteless.This product is readily soluble in chloroform, dissolves, in second in methanol
Slightly soluble in alcohol, the most insoluble in water.The fusing point of fusing point this product is 147～151 DEG C.Specific optical rotation takes this product, accurately weighed, adds first
The solution in every 1ml containing 40mg made by alcohol, measures in accordance with the law, calculates by dry product, and specific optical rotation should be-1 ° to+1 °.These product are pink
Color contamination suspension.These product dissolve easily absorption in gastric acid, when Both of gastric acidity reduces, absorption can be made to reduce.After absorption the most extensive
Distribution, can be to the joint fluid of inflammation, saliva, bile, urine, milk, tendon, skin soft tissue, excrement etc..To blood-cerebrospinal fluid barrier
Penetrance is poor, and in most cases, cerebrospinal fluid drug concentration is less than 1mg/L., but there is not yet relevant Ketoconazol/Clobetasol Propionate film
The preparation of agent.
Summary of the invention
It is an object of the invention to provide a kind of external skin stronger and more lasting to anti-inflammatory and anti-allergic effects
Ketoconazol/Clobetasol Propionate liniment.
Another object of the present invention discloses the preparation method of this liniment.
The present invention is achieved through the following technical solutions: a kind of Ketoconazol/Clobetasol Propionate liniment, represents with weight portion, including ketone health
Azoles 0.1 ~ 1.6g, tartaric acid 10 ~ 25g, Oleum menthae 5 ~ 15ml, polyvinyl alcohol 20 ~ 80g, ethylene glycol 50 ~ 150g, methyl hydroxybenzoate
1.2 ~ 3.6g, ethanol solution 200 ~ 600ml, enough purified water.
Mechanism of action is mainly the activity of the cytochrome P-450 of high selectivity interference fungus, thus suppresses fungus thin
The biosynthesis of ergosterol on after birth
In order to the present invention is better achieved, further, representing with weight portion, described ketoconazole is 0.5g, and tartaric acid is 12g,
Oleum menthae is 10ml, and polyvinyl alcohol is 70g, ethylene glycol 100g, and ethyl hydroxybenzoate is 1.8g, and ethanol solution is 400ml.
In order to the present invention is better achieved, further, described ethanol solution is my 80% ethanol solution of mass fraction.
The preparation method of a kind of Ketoconazol/Clobetasol Propionate liniment, comprises the following steps:
(1) 100g ethylene glycol adding 300ml purified water, stirring makes its mix homogeneously, it is thus achieved that mixed liquor；
(2) taking 70g polyvinyl alcohol to be completely soaked in the mixed liquor described in step (1), heating makes it be completely dissolved, and places cold
Rear stand-by；
(3) weighing 0.5g ketoconazole is and 12g tartaric acid, adds 10ml Oleum menthae, stirring, and is slowly added into step (2) simultaneously
In be dissolved with the mixed liquor of polyvinyl alcohol；
(4) 1g ethyl hydroxybenzoate is added, stirring while adding, after it is completely dissolved, adds Sufficient purified water and make 1000ml
Solution, after stirring, subpackage and get final product.
For the method that the present invention is better achieved, further, in described step (2), the process of heating uses steaming
Vapour bath heating.
For the method that the present invention is better achieved, further, in described step (4), stirring is all to pass through magnetic suspension
Blender has stirred.
The present invention compared with prior art, has the following advantages and beneficial effect:
After this liniment is applied to skin film forming, fungus, yeast, dimorphic fungus and the Mycophytes of skin surface is had antibacterial and kill
Bacterium effect, local topical, hardly through skin absorption, is used conveniently and safely, and therapeutic effect is good.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention is not limited to this,
Without departing from the idea case in the present invention described above, according to ordinary skill knowledge and customary means, make various replacing
Change and change, all should be included within the scope of the invention.
Embodiment:
The Ketoconazol/Clobetasol Propionate liniment of the present embodiment, represents with weight portion, and described ketoconazole is 0.5g, and tartaric acid is 12g, Herba Menthae
Oil is 10ml, and polyvinyl alcohol is 70g, ethylene glycol 100g, and ethyl hydroxybenzoate is 1.8g, and ethanol solution is 400ml, enough purification
Water.
Mainly with ketoconazole and tartaric acid as principal agent in the present embodiment, with polyvinyl alcohol as filmogen, with ethylene glycol and
Oleum menthae is that penetrating agent is made.
Ketoconazole is antifungal agent, to dermatophytosis such as trichophyta genus, Epidermophyton, Microsporon and yeast
Belong to candidiasis such as and have inhibitory action.
Its concrete preparation method, comprises the following steps:
(1) 100g ethylene glycol adding 300ml purified water, stirring makes its mix homogeneously, it is thus achieved that mixed liquor；
(2) taking 70g polyvinyl alcohol to be completely soaked in the mixed liquor described in step (1), heating makes it be completely dissolved, and places cold
Rear stand-by；
(3) weighing 0.5g ketoconazole is and 12g tartaric acid, adds 10ml Oleum menthae, stirring, and is slowly added into step (2) simultaneously
In be dissolved with the mixed liquor of polyvinyl alcohol；
(4) 1g ethyl hydroxybenzoate is added, stirring while adding, after it is completely dissolved, adds Sufficient purified water and make 1000ml
Solution, after stirring, subpackage and get final product.
Wherein, in described step (2), the process of heating uses steam bath to heat；In described step (4), stirring is all
Stirred by magnetic suspension blender..
One, irritation test
Take healthy rabbits 20, body weight 2.0～2.5kg, the not injured skin by rabbit spinal column both sides unhairing, expose both sides 5cm extremely
The epidermis of 7cm, is coated in this product 2mL left side and goes to hair-fields, and right side is coated with saline control, sees in 24 hours, 48 hours, 72 hours
Examining the reaction being coated with unconcerned position, result each coating area skin is all without phenomenons such as red and swollen, dermexanthesis, vesicles.Illustrate this product to skin without
Zest.
Two, film test is become
Dip this coating liquid with banister brush and coat thin layer the most gently, simultaneously patient 15 at the back of the hand or toe film
It is 90s that one layer of this product observes film formation time this liniment of result film formation time on a glass, is 70s on human body.This is described
The film property of product is good.
Three, clinical efficacy is investigated
Treatment group 80 example, male 50 examples, female 30 example, in age 12-72 year, the course of disease is between 1 month to 3 months.Matched group 58 example, man
26 examples, female 32 example, in age 8-68 year, average 2.5 months of the course of disease, above case suffers from neurodermatitis, eczema at different parts
Disease.
Treatment group: after cleaning focus face with medical alcohol, smears ketoconazole agent compound recipe liniment appropriate, three times a day, controls altogether
Treat 5 days.
Matched group: tartaric acid ointment, outer wiping, three times a day, treatment 14 days altogether.
Observational technique and curative effect determinate standard: carry out with reference to clinical efficacy criterion.
Therapeutic outcome: treatment group, average cure time 5 days, transference cure, cure rate 85.1%, effective percentage 92.1%；Comparison
Group average cure time 12 days, cure rate 53.3%, effective percentage 69.6%.Treatment group is substantially better than matched group.Although having shown that
With describe embodiments of the invention, it will be understood by those skilled in the art that: without departing from the principle of the present invention and ancestor
These embodiments can be carried out multiple change under purport, revise, replace and modification, the scope of the present invention by claim and etc.
Jljl limits.
Claims (6)
1. a Ketoconazol/Clobetasol Propionate liniment, it is characterised in that represent with weight portion, including ketoconazole 0.1 ~ 1.6g, tartaric acid
10 ~ 25g, Oleum menthae 5 ~ 15ml, polyvinyl alcohol 20 ~ 80g, ethylene glycol 50 ~ 150g, methyl hydroxybenzoate 1.2 ~ 3.6g, ethanol solution
200 ~ 600ml, enough purified water.
A kind of Ketoconazol/Clobetasol Propionate liniment the most according to claim 1, it is characterised in that represent with weight portion, described ketone
Health azoles is 0.5g, and tartaric acid is 12g, and Oleum menthae is 10ml, and polyvinyl alcohol is 70g, ethylene glycol 100g, and ethyl hydroxybenzoate is
1.8g, ethanol solution is 400ml.
A kind of Ketoconazol/Clobetasol Propionate liniment the most according to claim 1 and 2, it is characterised in that described ethanol solution is matter
Amount my 80% ethanol solution of mark.
4. the preparation method of a Ketoconazol/Clobetasol Propionate liniment, it is characterised in that: comprise the following steps:
(1) 100g ethylene glycol adding 300ml purified water, stirring makes its mix homogeneously, it is thus achieved that mixed liquor；
(2) taking 70g polyvinyl alcohol to be completely soaked in the mixed liquor described in step (1), heating makes it be completely dissolved, and places cold
Rear stand-by；
(3) weighing 0.5g ketoconazole is and 12g tartaric acid, adds 10ml Oleum menthae, stirring, and is slowly added into step (2) simultaneously
In be dissolved with the mixed liquor of polyvinyl alcohol；
(4) 1g ethyl hydroxybenzoate is added, stirring while adding, after it is completely dissolved, adds Sufficient purified water and make 1000ml
Solution, after stirring, subpackage and get final product.
The preparation method of a kind of Ketoconazol/Clobetasol Propionate liniment the most according to claim 1, it is characterised in that: described step
(2) in, the process of heating uses steam bath to heat.
The preparation method of a kind of Ketoconazol/Clobetasol Propionate liniment the most according to claim 1, it is characterised in that: described step
(4), in, stirring is all to have been stirred by magnetic suspension blender.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610611441.4A CN106138055A (en) | 2016-07-30 | 2016-07-30 | A kind of Ketoconazol/Clobetasol Propionate liniment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610611441.4A CN106138055A (en) | 2016-07-30 | 2016-07-30 | A kind of Ketoconazol/Clobetasol Propionate liniment and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138055A true CN106138055A (en) | 2016-11-23 |
Family
ID=57327665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610611441.4A Withdrawn CN106138055A (en) | 2016-07-30 | 2016-07-30 | A kind of Ketoconazol/Clobetasol Propionate liniment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138055A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108169154A (en) * | 2017-12-27 | 2018-06-15 | 佛山市南海东方澳龙制药有限公司 | The method for detecting Determination of Ketoconazole in compound ketoconazole ointment |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379862A (en) * | 2011-11-03 | 2012-03-21 | 北京泰德制药股份有限公司 | Spirosal-containing hydrophilic cataplasm |
| CN105616388A (en) * | 2016-02-29 | 2016-06-01 | 成都艾比科生物科技有限公司 | Compound clobetasol propionate coating agent |
| CN105687164A (en) * | 2016-02-29 | 2016-06-22 | 成都艾比科生物科技有限公司 | Preparation method of compound clobetasol propionate liniment |
-
2016
- 2016-07-30 CN CN201610611441.4A patent/CN106138055A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379862A (en) * | 2011-11-03 | 2012-03-21 | 北京泰德制药股份有限公司 | Spirosal-containing hydrophilic cataplasm |
| CN105616388A (en) * | 2016-02-29 | 2016-06-01 | 成都艾比科生物科技有限公司 | Compound clobetasol propionate coating agent |
| CN105687164A (en) * | 2016-02-29 | 2016-06-22 | 成都艾比科生物科技有限公司 | Preparation method of compound clobetasol propionate liniment |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108169154A (en) * | 2017-12-27 | 2018-06-15 | 佛山市南海东方澳龙制药有限公司 | The method for detecting Determination of Ketoconazole in compound ketoconazole ointment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102985091A (en) | Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | |
| EP2266626B1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
| CN100998575B (en) | Finger nail coating agent of antifungal agent and its preparing method | |
| CN108137612A (en) | The preparation of soft anticholinergic drug analog | |
| CN106138055A (en) | A kind of Ketoconazol/Clobetasol Propionate liniment and preparation method thereof | |
| TW208658B (en) | ||
| CN104224691B (en) | A kind of external preparation of moxifloxacin hydrochloride and preparation method thereof | |
| WO2005102981A1 (en) | Novel compounds and medicinal use thereof | |
| CN105687164A (en) | Preparation method of compound clobetasol propionate liniment | |
| CN105832808A (en) | Preparation method of traditional Chinese medicine compound liniment for relieving swelling and pain | |
| CN103142622B (en) | Triamcinolone acetonide econazole emulsion-type gel | |
| CN1062132C (en) | Cream for curing eczema | |
| CN104771405A (en) | Compound terbinafine preparation and applications thereof | |
| CN105213408A (en) | A kind of compound recipe triamcinolone acetonide liniment and preparation method thereof | |
| CN105616388A (en) | Compound clobetasol propionate coating agent | |
| CN104523711B (en) | Ketone Kang Tasuo emulsifiable pastes and preparation method thereof | |
| WO2008047983A1 (en) | Composition for preventing and treating inflammatory bowel diseases | |
| CN106794123A (en) | The composition of the material of the expression comprising regulation ABH antigens | |
| CN107412647A (en) | A kind of external preparation for the antipruritic lasting that sterilizes | |
| JPS62155214A (en) | Antiinflammatory drug and method | |
| CN105055464A (en) | Compound golden larch bark coating agent and preparation method thereof | |
| CN107823124A (en) | A kind of Olopatadine hydrochloride topical composition and its cream | |
| CN103142619B (en) | Pharmaceutical composition for treating dermatitis and preparation method thereof | |
| CN101049286B (en) | Gel preparation of Ciclopirox Olamine | |
| CN105998146A (en) | Traditional Chinese medicine compound film coating agent for relieving swelling and pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161123 |